

Hang Quach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4691929/publications.pdf>

Version: 2024-02-01

140
papers

6,303
citations

201674

27
h-index

74163

75
g-index

140
all docs

140
docs citations

140
times ranked

6308
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	1.4	64
2	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 65-76.	10.7	80
3	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	7.2	39
4	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase II 2 trial. <i>Blood Cancer Journal</i> , 2022, 12, 9.	6.2	14
5	MRD end point in myeloma: ready for prime time?. <i>Blood</i> , 2022, 139, 799-802.	1.4	5
6	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	5.2	14
7	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	1.2	11
8	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
9	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 4506-4515.	5.2	4
10	Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8037-8037.	1.6	0
11	Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8017-8017.	1.6	7
12	Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8006-8006.	1.6	14
13	Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM): Interim phase 1b study results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8025-8025.	1.6	4
14	CAMMA 3: A multicenter phase 1b trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8070-TPS8070.	1.6	1
15	Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8019-8019.	1.6	11
16	Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (<sc>MRDR</sc>). <i>British Journal of Haematology</i> , 2022, 198, 830-837.	2.5	8
17	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 112-117.	1.3	5
18	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 330-336.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study. <i>Mycoses</i> , 2021, 64, 30-34.	4.0	5
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
21	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
22	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021, 56, 2533-2543.	2.4	7
23	Myeloma natural killer cells are exhausted and have impaired regulation of activation. <i>Haematologica</i> , 2021, 106, 2522-2526.	3.5	8
24	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8019-8019.	1.6	2
25	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
26	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. <i>British Journal of Haematology</i> , 2021, 194, 784-788.	2.5	7
27	<sc>COVID</sc>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.8	12
28	A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8055-TPS8055.	1.6	3
29	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	2.4	23
30	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-eligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , 2021, 107, 497-499.	2.2	2
31	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
32	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e510-e520.	0.4	12
33	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 444-450.e3.	0.4	17
34	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	4.1	7
35	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
36	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , 2021, 39, 3602-3612.	1.6	44

#	ARTICLE	IF	CITATIONS
37	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
38	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). <i>Haematologica</i> , 2021, , .	3.5	0
39	Successful identification of predictive profiles for infection utilising systemsâ€level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1235.	3.8	3
40	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1582-1596.	10.7	141
41	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
42	Assessing the Immune Tumour Microenvironment (iTME) Using Multiplex Immunofluorescence Histochemistry (mIHC) Demonstrates Close Proximity of Cytotoxic T-Cells to Plasma Cells (PC) in Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2021, 138, 4705-4705.	1.4	0
43	Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. <i>Blood</i> , 2021, 138, 1663-1663.	1.4	1
44	Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Irl Study of the Australian Myeloma Research Consortium (AMaRC 18-02). <i>Blood</i> , 2021, 138, 1671-1671.	1.4	1
45	Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. <i>Blood</i> , 2021, 138, 1665-1665.	1.4	0
46	A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). <i>Blood</i> , 2021, 138, 2728-2728.	1.4	1
47	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	1.4	1
48	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , 2021, 138, 4095-4095.	1.4	0
49	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , 2021, 138, 1646-1646.	1.4	1
50	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
51	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
52	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
53	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2153.	4.8	16
54	Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 1201-1210.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. <i>Blood Advances</i> , 2020, 4, 4802-4811.	5.2	33
56	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2020, 396, 186-197.	13.7	299
57	Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. <i>Cancers</i> , 2020, 12, 3488.	3.7	6
58	Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 724-735.	0.4	5
59	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
60	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	13.7	188
61	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 667-679.	0.8	37
62	Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (MyePROMPT) – a pilot randomized controlled trial. <i>American Journal of Hematology</i> , 2020, 95, E178-E181.	4.1	6
63	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2837-2846.	1.8	9
64	Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone. <i>Blood</i> , 2020, 136, 18-20.	1.4	1
65	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 19-20.	1.4	27
66	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8502-8502.	1.6	32
67	Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8511-8511.	1.6	11
68	Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8527-8527.	1.6	5
69	DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS8556-TPS8556.	1.6	13
70	Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 1-2.	1.4	2
71	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 13544.	3.3	8
72	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	27.0	684

#	ARTICLE	IF	CITATIONS
73	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e415-e424.	0.4	13
74	Cell surface glucose-regulated protein 78 (GRP78) is upregulated in plasma cells of patients with multiple myeloma compared to monoclonal gammopathy of uncertain significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e95-e96.	0.4	1
75	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
76	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	1.4	26
77	Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone. <i>Blood</i> , 2019, 134, 4376-4376.	1.4	1
78	Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis. <i>Blood</i> , 2019, 134, 269-269.	1.4	11
79	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). <i>Blood</i> , 2019, 134, LBA-6-LBA-6.	1.4	27
80	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8035-8035.	1.6	4
81	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8040-8040.	1.6	1
82	Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8053-TPS8053.	1.6	4
83	Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 4159.	3.3	79
84	Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2018, 48, 210-220.	0.8	31
85	Real-world™ Australian experience of pomalidomide for relapsed and refractory myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1514-1516.	1.3	11
86	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1530-1542.	10.7	91
87	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
88	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
89	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	1.4	30
90	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. <i>Blood</i> , 2018, 132, 3288-3288.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. <i>Blood</i> , 2018, 132, 3279-3279.	1.4	0
92	Characterization of Cardiovascular Adverse Events and B-Type Natriuretic Peptide Levels in Patients with Multiple Myeloma Who Are Treated with Carfilzomib. <i>Blood</i> , 2018, 132, 1956-1956.	1.4	0
93	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.8	10
94	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
95	Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1067-1076.	2.3	21
96	Nilotinib dose optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. <i>British Journal of Haematology</i> , 2017, 179, 219-228.	2.5	14
97	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
98	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8006-8006.	1.6	18
99	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8036-8036.	1.6	4
100	Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial. <i>Blood</i> , 2017, 130, 839-839.	1.4	4
101	Myeloma of the central nervous system – an ongoing conundrum!. <i>Leukemia and Lymphoma</i> , 2016, 57, 1505-1506.	1.3	3
102	Spontaneous onset and transplant models of the V λ *MYC mouse show immunological sequelae comparable to human multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 259.	4.4	21
103	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016, 538, 518-522.	27.8	159
104	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. <i>BMC Medical Research Methodology</i> , 2016, 16, 151.	3.1	25
105	Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor. <i>Blood</i> , 2016, 128, 3313-3313.	1.4	5
106	A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy. <i>Blood</i> , 2016, 128, 4515-4515.	1.4	1
107	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. <i>Blood</i> , 2016, 128, 5199-5199.	1.4	1
108	Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma". <i>Haematologica</i> , 2015, 100, e379-e379.	3.5	4

#	ARTICLE	IF	CITATIONS
109	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	27.0	1,261
110	The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit. <i>American Journal of Hematology</i> , 2015, 90, E86-91.	4.1	7
111	Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the <sc>M</sc>yeloma <sc>F</sc>oundation of <sc>A</sc>ustralia <sc>M</sc>edical and <sc>S</sc>cientific <sc>A</sc>dvisory <sc>G</sc>roup. <i>Internal Medicine Journal</i> , 2015, 45, 94-105.	0.8	13
112	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of <sc>A</sc>ustralia <sc>M</sc>edical and <sc>S</sc>cientific <sc>A</sc>dvisory <sc>G</sc>roup. <i>Internal Medicine Journal</i> , 2015, 45, 335-343.	0.8	6
113	Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2185-2186.	1.3	23
114	Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. <i>Blood</i> , 2015, 126, 344-344.	1.4	2
115	High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma. <i>Blood</i> , 2015, 126, 4206-4206.	1.4	2
116	Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials. <i>Blood</i> , 2015, 126, 4236-4236.	1.4	2
117	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Na ⁺ ve CLL/SL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	1.4	2
118	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid [®]) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. <i>European Journal of Cancer</i> , 2013, 49, 2869-2876.	2.8	114
119	Radiotherapy in orbital lymphoma: optimizing the backbone to build upon. <i>Leukemia and Lymphoma</i> , 2013, 54, 445-446.	1.3	0
120	CD57+ NK CELLS ARE Increased In Patients With Multiple Myeloma and ARE Primed Effectors For ADCC, But NOT Natural Cytotoxicity. <i>Blood</i> , 2013, 122, 1904-1904.	1.4	8
121	Serum protein electrophoresis: a precautionary tale. <i>Pathology</i> , 2012, 44, 371-373.	0.6	0
122	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia. <i>Aids</i> , 2012, 26, 1977-1979.	2.2	8
123	Lenalidomide in multiple myeloma: Current status and future potential. <i>American Journal of Hematology</i> , 2012, 87, 1089-1095.	4.1	25
124	Managing multiple myeloma in the elderly: are we making progress?. <i>Expert Review of Hematology</i> , 2011, 4, 301-315.	2.2	6
125	Reversal of Transfusion Dependence by Tumor Necrosis Factor Inhibitor Treatment in a Patient With Concurrent Rheumatoid Arthritis and Primary Myelofibrosis. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 211-213.	0.9	4
126	A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood</i> , 2011, 118, 6274-6283.	1.4	83

#	ARTICLE	IF	CITATIONS
127	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. <i>Blood</i> , 2011, 117, 1605-1613.	1.4	152
128	Response: dexamethasone dose alters expression of NK activating receptors in vivo. <i>Blood</i> , 2011, 118, 6466-6468.	1.4	4
129	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. <i>Annals of Hematology</i> , 2011, 90, 989-990.	1.8	27
130	Drug-mediated and cellular immunotherapy in multiple myeloma. <i>Immunotherapy</i> , 2010, 2, 243-255.	2.0	13
131	Extra-nasal NK/T cell lymphoma masquerading as renal infarction. <i>Leukemia and Lymphoma</i> , 2010, 51, 1139-1141.	1.3	4
132	Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial. <i>Blood</i> , 2010, 116, 1961-1961.	1.4	10
133	Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 5037-5037.	1.4	2
134	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. <i>Blood</i> , 2010, 116, 1776-1776.	1.4	4
135	Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2009, 84, 715-719.	4.1	23
136	Predicting durable remissions following thalidomide therapy for relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 223-229.	1.3	9
137	In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2008, 31, 166-179.	2.4	38
138	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. <i>Blood</i> , 2008, 112, 1696-1696.	1.4	19
139	Treatment Strategies in Elderly Patients with Multiple Myeloma. <i>Drugs and Aging</i> , 2007, 24, 829-850.	2.7	4
140	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. <i>Blood</i> , 2007, 110, 1167-1167.	1.4	9